The supply agreement is designed to support the evaluation of Immuneerings lead candidate, atebimetinib (IMM-1-104), a novel dual MEK inhibitor, in combination with olomorasib in a planned Phase II trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy
Answer: Most side effects are mild and dose-related
It also supports the metabolism of fats and carbohydrates, fueling mitochondrial energy production
If you are currently taking one of these medications, you must know how many milligrams (mg) you are taking BEFORE chosing your membership tier
News / Blog ATTENTION
Grundy MM, Deglaire A, Le Feunteun S, Reboul E, Moughan PJ, Wilde PJ, et al